Yes — under the 2026 iPLEDGE changes, prescribers may allow home pregnancy tests during and after isotretinoin treatment. iPLEDGE is the FDA safety program for isotretinoin, a drug for severe recalcitrant nodular acne in patients age 12 and older. The FDA approved the modifications on Feb.
9, 2026, with changes taking effect about 180 days later around Aug. 8-9, 2026, according to the National Community Pharmacists Association approval summary. Planned home testing reduces lab trips, but it does not remove other safeguards.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What changes for follow-up tests?
- What still needs a clinic or lab visit?
- Why is home testing not automatic?
- How can parents plan for the next visit?
What changes for follow-up tests?
During and after treatment, a prescriber may now allow a patient who can become pregnant to complete a required test at home. Dermatology Times, reporting the FDA safety-program update, describes this as a prescriber choice testing update.
The update also drops the rule that tests be done in a CLIA-certified laboratory. This change was described in FDA materials reported by Cardiology Advisor. It also ends the 19-day lockout after missing the 7-day prescription window.
What still needs a clinic or lab visit?
All pregnancy testing before the first isotretinoin dose must still occur in a medical setting. The FDA medical-organizations letter lists a prescriber office, clinic, or laboratory as acceptable sites prescriber letter.
That first in-person test matters because isotretinoin can cause fetal malformations, spontaneous abortion, and premature birth. FDA prescribing information lists severe recalcitrant nodular acne in nonpregnant patients age 12 and older as the indication. Monthly tests remain required after treatment starts.
Why is home testing not automatic?
A prescriber must set up procedures to ensure accurate documentation when relying on patient-performed tests. The Journal of Dermatology for NPs/PAs reports this requirement alongside FDA enforcement discretion until implementation.
So families should not assume every clinic will offer home testing immediately. Ask these practical questions at the visit:.
- Will this practice allow home tests for follow-up months
- How should we record the date, result, and test used
- When should we test, send proof, and call about a missed or unclear result
How can parents plan for the next visit?
For many families, the practical effect is fewer lab visits and easier telemedicine follow-up. Healio Dermatology reports that benefit, while noting monthly tests, two contraception methods or abstinence, and prescriber-pharmacy enrollment remain mandatory. Counseling documentation for patients who cannot become pregnant changes from monthly to enrollment only, though reinforcement during treatment is recommended.
That change comes from the FDA website-update document. Enrollment itself still applies to prescriber and pharmacy. Bring your teen's contraception or abstinence plan, test calendar, and pharmacy details to the next visit and confirm how the clinic wants home results sent.
You Might Also Like
- Planned Home Pregnancy Testing Under the 2026 iPLEDGE Changes: What Changed, What Did Not, and What Comes Next for Parents of Teens With Severe Acne
- Pretreatment Pregnancy Testing Under iPLEDGE in 2026: What Changed, What Did Not, and What Comes Next for Parents of Teens With Severe Acne
- Pediatric Acne and Rosacea at the 2026 AAD Annual Meeting: Evidence and Practice Questions Still Open for Parents of Teens With Acne